This episode is an interview with Dr. Wouter Vaes, the Chief Science Officer of Peregrion. We discuss how accelerator mass spectrometry is being used in early clinical development for drug metabolism and pharmacokinetics. We discuss using this technology to support development of oncology agents, determining absolute bioavailability without IV toxicology work, and more. Links discussed in the show:You can contact Wouter by email: wouter.vaes@peregrion.com Connect with Peregrion on LinkedIn or their websiteSymposium on microtracer studies FDA guidance on safety testing of drug metabolitesWhite paper on human ADME data You can connect with Nathan on LinkedIn and send me a message Send Nathan a message Sign up for Nathan’s newsletter Copyright Teuscher Solutions LLCAll Rights Reserved
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Examining Volume of Distribution (Ep. 56)
Talking about data science with Mike Stackhouse (Ep. 55)
Using AI tools for regulatory intelligence (Ep. 53)
When to use model-informed drug development (Ep. 52)
Free AI-powered recaps of Clinical Pharmacology Podcast with Nathan Teuscher and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.